SOLEDUM® 

– To help you breathe freely

Soledum® with its active ingredient cineole targets the symptoms of respiratory diseases such as common cold (blocked or runny nose, head pressure, cough with more or less thick mucus), bronchitis and sinusitis.

Soledum® product range

We offer medicines with the pure natural substance cineole to treat the symptoms of inflammatory airway diseases such as common cold, bronchitis, sinusitis.

The natural active ingredient cineole removes mucus and has anti-inflammatory and laboratory proven antimicrobial effects - the small capsule with a great effect in the upper and lower airways - against the stressful symptoms in common cold, bronchitis and sinusitis.

The efficacy of SOLEDUM® has been proven for decades.

Cineole is an active ingredient of herbal origin for the upper and lower respiratory tract. That is the reason for our research at Klosterfrau Healthcare Group: to be able to offer suitable products for various indications.

With Soledum® Capsules forte and Soledum® Capsules, the Klosterfrau Healthcare Group has succeeded in developing highly effective medicinal products with the active ingredient cineole. During exhalation cineole comes into contact with the airways which are inflamed and congested in common cold, bronchitis and sinusitis. Cineole exerts its anti-inflammatory, secretolytic and antimicrobial effects where needed: at the inflamed mucous membrane of the airways.

Find out more about Soledum®:

Proven efficacy with pure cineole, 

the active ingredient of SOLEDUM® for decades

Committed to the Klosterfrau Healthcare Group tradition, we also rely on a natural active ingredient for Soledum® Capsules forte and Soledum® Capsules: The clinically proven efficacy of Soledum® is due to the active ingredient: pure cineole.

Cineole has been known for a long time as the main active component of eucalyptus oil, but intensive work in research and development was required before this valuable natural substance could be isolated from the leaves of the eucalyptus tree and brought into a suitable medicinal dosage form. Since then, cineole has been available in pure form from the plant and can be processed as a single active ingredient in Soledum®.

Cineole is approved for various indications - and its diverse effects have been proven in many studies*. The secretolytic and mucoregulatory effect is an important and necessary property for use in the indication of a common cold - this is how cineole clears the airways. In addition, important anti-inflammatory, antibacterial and antiviral properties for the respiratory tract have been demonstrated for cineole. Hardly any other natural substance combines similarly diverse effects and has been researched as well as cineole.

Cineole is not only effective - it is also well tolerated. It is available as Soledum® Capsules forte (200 mg cineole per capsule) and Soledum® Capsules (100 mg cineole per capsule). Two tried and tested medicines with the active ingredient cineole.

Cineole - the main active component of eucalyptus oil

A helpful companion 

also for COPD and asthma.

Soledum® is also approved for the co-medication of chronic and inflammatory respiratory tract disorders.

A common cold is usually overcome in seven to ten days. But what if bronchitis becomes chronic, or chronic obstructive pulmonary disease (COPD) is present?

The meaning of the acronym COPD is not yet common knowledge, neither in Germany nor in other countries. According to the World Health Organization (WHO), almost three million people die as a result of COPD every year, and it is estimated that around 15% of those over 40 and almost 30% of those over 70 suffer from COPD.

(Source: https://www.umweltbundesamt.de/themen/gesundheit/umweltmedizin/copd, accessed August 2020)

It has been proven that the power of cineole can also have a positive effect as an additional treatment for these chronic and inflammatory lung diseases.

The main cause of COPD is smoking. The symptoms are coughing with sputum and a progressive narrowing of the airways, which initially leads to shortness of breath during physical exertion and later also when at rest. Over the course of the chronic illness, disease flare-ups occur again and again (so-called exacerbations), which, depending on the severity, may have to be treated in hospital. It should not get that far in the first place. A clinical study by the University of Nuremberg-Erlangen with COPD patients has shown that the additional treatment with cineole (Soledum®) can significantly reduce the number, severity and duration of exacerbations.

Asthma is another chronic inflammatory disease of the airways. Sudden constriction of the airways with spasms of the bronchi can occur, sometimes also with excessive mucus formation. A differentiation is made between allergic and non-allergic asthma. In a clinical study with asthma patients, during twelve-week additional treatment with cineole (3 times 200 mg per day), the corticosteroid dose of the patients could be reduced step by step under medical supervision. This result emphazises the high therapeutic benefit of the anti-inflammatory effect of cineole.

SOLEDUM® - convincing clinical data. 

Controlled clinical trials prove the efficacy.

An effective natural therapeutic substance that is well tolerated – this is the guiding principle of the Klosterfrau Healthcare Group for the development of medicines. With the active ingredient cineole, Soledum® has now matured into a classic medicine for common colds, bronchitis and sinusitis. Clinical studies* have proven that in case of inflammation of the paranasal sinuses and nasal mucosa (so-called rhinosinusitis), the symptoms in the patients treated with cineole (Soledum®) had already significantly improved by the fourth day of therapy compared to the patients who received placebo. This is an important treatment success with cineole if you consider that acute, untreated rhinosinusitis is defined with a temporal course of the symptoms of up to 12 weeks.

The active ingredient cineole is recommended in various guidelines* for rhinosinusitis, cough and COPD and also in the care guideline asthma*.

As we have done for decades, we will continue to work on researching the positive properties of the natural active ingredient cineole. 

Source

*National Supply Guideline Asthma 2020: Federal Medical Association, National Association of Statutory Health Insurance Physicians, Working Group of Scientific Medical Societies. Long Version, 4. Edition. Version 1. 2020 (cited 2021 May 4) DOI: 10.6101/AZQ/000469.  Available from: www.asthma.versorgungsleitlinien.de.

Kehrl W et al.: Therapy for Acute Nonpurulent Rhinosinusitis With Cineole: Results of a Double-Blind, Randomized, Placebo-Controlled Trial. The Laryngoscope 2004; Vol 114 No 4: 738–742.

Fischer J, Dethlefsen U. Efficacy of cineole in patients suffering from acute bronchitis: a placebo-controlled double-blind trial. Cough 2013, 9: 25. coughjournal.com/content/9/1/25

Worth H, Dethlefsen U. Patients with Asthma Benefit from Concomitant Therapy with Cineole: A Placebo-Controlled, Double-Blind Trial. Journal of Asthma 2012; 49 (8): 849–853.

Worth H et al.: Concomitant therapy with Cineole (Eucalyptole) reduces exacerbations in COPD: A placebo-controlled double-blind trial. Respiratory Research 2009; 10:69.

Stuck BA, Popert U, Beule A et al. Rhinosinusitis S2k guideline. AWMF register no. 017/049 and 053-012. Editor: German Society for Oto-Rhino-Laryngology, Head and Neck Surgery e. V. (DGHNO-KHC), German Society for General Medicine and Family Medicine (DEGAM), Berlin. Status 04/2017. https://www.awmf.org/uploads/tx_szleitlinien/017-049_und_053-012_S2k_Rhinosinusitis_2019-04_01.pdf (accessed on: 13 August, 2020).

Kardos P, Dinh QT, Fuchs K-H et al. Guideline of the German Society for Pneumology and Respiratory Medicine for the diagnosis and therapy of adult patients with cough. Pneumology 2019; 73: 143-180.

Vogelmeier C, Buhl R, Burghuber O et al. Guideline for the diagnosis and treatment of patients with chronic obstructive bronchitis and pulmonary emphysema (COPD). Pneumology 2018; 72: 253-308.

All information concerning our products and ingredients
  • Soledum® – Legal Texts

    Soledum® Capsules, Soledum Capsules forte Active ingredient: cineole
    Soledum® Capsules forte
    Active ingredient: cineole 
    Indication: For treatment of symptoms of bronchitis and common colds affecting the respiratory tract. For the co-medication of chronic and inflammatory respiratory tract disorders (e.g. of the paranasal sinuses). For information on risks and side effects, read the package leaflet and ask your doctor or pharmacist.
    Soledum® Capsules
    Active ingredient: cineole 
    Indication: For treatment of symptoms of bronchitis and common colds affecting the respiratory tract. For the co-medication of chronic and inflammatory respiratory tract disorders (e.g. of the paranasal sinuses). For information on risks and side effects, read the package leaflet and ask your doctor or pharmacist.


More brands

 

Effective against sore throat

 

For sore throat and cough in children

 

The nasal spray with ActionPlus

 

Treatment of cystitis

 

The universal herbal healing power

Contact

Do you have questions? Your requests or suggestions are very welcome and we are happy to help you. We will process your request as quickly as possible. You will receive a copy of your message by e-mail.